Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
Sun Pharma's Dadra facility receives OAI status from US FDA
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Subscribe To Our Newsletter & Stay Updated